Experimental and Clinical Evaluation in Man of Hexamethonium (C6), a New Ganglionic Blocking Agent

Circulation - United States
doi 10.1161/01.cir.2.6.828
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Clinical Evaluation of Practolol, a New Cardioselective Beta-Blocking Agent in Angina Pectoris

BMJ
1970English

Hemodynamic Effects of Tilisolol, a New .BETA.-adrenergic Blocking Agent With Vasodilating Property, and Doxazosin, a New .ALPHA.-adrenergic Blocking Agent, in Essential Hypertension.

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1988English

The Phase 1 Study of Bucumolol, a New Β-Blocking Agent

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1980English

Studies on the Blocking Effect of Autonomic Ganglionic Blocking Agents Upon the Parasympathetic Nervous System

Folia Pharmacologica Japonica
Pharmacology
1960English

Vascular Reactivity in Experimental Hypertension Measured After Hexamethonium

Circulation
Cardiovascular MedicinePhysiologyCardiology
1958English

Studies on Experimental and Clinical Hypochloremia in Man 1

Journal of Clinical Investigation
Medicine
1943English

Antihypertensive and Hemodynamic Properties of the New Beta Adrenergic Blocking Agent Timolol

Circulation
Cardiovascular MedicinePhysiologyCardiology
1973English

The Pharmacology of Pancuronium Bromide (ORG.NA97), a New Potent Steroidal Neuromuscular Blocking Agent

British Journal of Pharmacology and Chemotherapy
1968English

Comparison of Hemodynamic Effects Between .BETA.-blocking Agents and a New Antianginal Agent, Diltiazem Hydrochloride.

Japanese Circulation Journal
1979English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy